Brief: Oncolytics Biotech, Solti Present New Clinical Data Demonstrating Pelareorep's Potential To Improve The Prognosis Of Breast Cancer Patients
04/05/2022 14:14
May 4 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® AND SOLTI PRESENT NEW CLINICAL
BIOMARKER
DATA DEMONSTRATING PELAREOREP'S POTENTIAL TO IMPROVE THE
PROGNOSIS OF BREAST CANCER PATIENTS AT THE ESMO BREAST CANCER
MEETING
Source text for Eikon: ID:nCNWTl6jca
Further company coverage: ONC.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer